WO2000047740A3 - Tnf-related proteins - Google Patents

Tnf-related proteins Download PDF

Info

Publication number
WO2000047740A3
WO2000047740A3 PCT/US2000/003653 US0003653W WO0047740A3 WO 2000047740 A3 WO2000047740 A3 WO 2000047740A3 US 0003653 W US0003653 W US 0003653W WO 0047740 A3 WO0047740 A3 WO 0047740A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
related proteins
cells
amino acids
antibodies
Prior art date
Application number
PCT/US2000/003653
Other languages
French (fr)
Other versions
WO2000047740A2 (en
WO2000047740A9 (en
Inventor
William J Boyle
Hailing Hsu
Original Assignee
Amgen Inc
William J Boyle
Hailing Hsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, William J Boyle, Hailing Hsu filed Critical Amgen Inc
Priority to AU28804/00A priority Critical patent/AU2880400A/en
Publication of WO2000047740A2 publication Critical patent/WO2000047740A2/en
Publication of WO2000047740A3 publication Critical patent/WO2000047740A3/en
Publication of WO2000047740A9 publication Critical patent/WO2000047740A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Abstract

A member of the tumor necrosis factor family and associated antibodies and uses are described. This member is primarily expressed in B cells and its expression correlates to increases in the number of B cells and immunoglobulins produced. The human ortholog contains 285 amino acids; the mouse ortholog, 309 amino acids. The protein is a type II transmembrane protein and has an amino terminal cytoplasmic domain, a transmembrane domain, and a carboxy terminal extracellular domain. TNF-related proteins of the invention may be membrane-associated or in soluble form, recombinantly produced or isolated after natural production. The invention provides for nucleic acids encoding such TNF-related proteins, vectors and host cells expressing the polypeptides, and methods for producting recombinant porteins. Antibodies, fragments, and related fusion proteins and derivatives may be used as agonists or antagonists of AGP-3 related activity.
PCT/US2000/003653 1999-02-12 2000-02-11 Tnf-related proteins WO2000047740A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU28804/00A AU2880400A (en) 1999-02-12 2000-02-11 Tnf-related proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11990699P 1999-02-12 1999-02-12
US60/119,906 1999-02-12
US16627199P 1999-11-18 1999-11-18
US60/166,271 1999-11-18

Publications (3)

Publication Number Publication Date
WO2000047740A2 WO2000047740A2 (en) 2000-08-17
WO2000047740A3 true WO2000047740A3 (en) 2000-12-07
WO2000047740A9 WO2000047740A9 (en) 2002-04-04

Family

ID=26817849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003653 WO2000047740A2 (en) 1999-02-12 2000-02-11 Tnf-related proteins

Country Status (2)

Country Link
AU (1) AU2880400A (en)
WO (1) WO2000047740A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
DE69934425T2 (en) 1998-10-23 2007-09-27 Amgen Inc., Thousand Oaks THROMBOPOIETIN SUBSTITUTE
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
PT2281843T (en) * 2000-06-16 2017-01-02 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
NZ542878A (en) 2001-05-11 2007-06-29 Amgen Inc Peptides and related molecules that bind to tall-1 in particular SEQ ID NO:104
ES2706902T3 (en) 2001-06-26 2019-04-01 Amgen Inc Antibodies for OPGL
US20070249530A1 (en) 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
AU2005295713B2 (en) 2004-10-13 2011-06-16 The Washington University Use of BAFF to treat sepsis
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
JO3324B1 (en) 2006-04-21 2019-03-13 Amgen Inc Lyophilized Therapeutic Peptibody Formulations
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US20210238295A1 (en) * 2018-04-26 2021-08-05 University Of Virginia Patent Foundation Compositions and methods for treating abdominal aortic aneurysm

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0675200A1 (en) * 1993-11-10 1995-10-04 Mochida Pharmaceutical Co., Ltd. A FAS ligand, a fragment thereof and DNA encoding the same
WO1997018307A1 (en) * 1995-11-16 1997-05-22 Novartis Ag Fas ligand fusion protein
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
WO1997046686A2 (en) * 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
EP0869180A1 (en) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation A TNF homologue, TL5
WO1998049305A1 (en) * 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
WO1998055621A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1999026977A1 (en) * 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2
WO2000024782A2 (en) * 1998-10-23 2000-05-04 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0675200A1 (en) * 1993-11-10 1995-10-04 Mochida Pharmaceutical Co., Ltd. A FAS ligand, a fragment thereof and DNA encoding the same
WO1997018307A1 (en) * 1995-11-16 1997-05-22 Novartis Ag Fas ligand fusion protein
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
WO1997046686A2 (en) * 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
EP0869180A1 (en) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation A TNF homologue, TL5
WO1998049305A1 (en) * 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
WO1998055621A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1999026977A1 (en) * 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2
WO2000024782A2 (en) * 1998-10-23 2000-05-04 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANILENKO D M (REPRINT) ET AL: "AGP - 1, a novel member of the tumor necrosis factor family, induces hepatic necrosis and inflammation in transgenic mice", FASEB JOURNAL,US,FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, vol. 11, no. 3, 28 February 1997 (1997-02-28), XP002045026, ISSN: 0892-6638 *
SCHNEIDER P ET AL: "BAFF, A NOVEL LIGAND OF THE TUMOR NECROSIS FACTOR FAMILY, STIMULATES B CELL GROWTH", JOURNAL OF EXPERIMENTAL MEDICINE,TOKYO,JP, vol. 189, no. 11, 7 June 1999 (1999-06-07), pages 1747 - 1756, XP000915409, ISSN: 0022-1007 *
YAMAGUCHI K ET AL: "Characterisation of structural domains of human osteoclastogenesis inhibitory factor", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 9, no. 273, 27 February 1998 (1998-02-27), pages 5117 - 5123, XP002077021, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2000047740A2 (en) 2000-08-17
AU2880400A (en) 2000-08-29
WO2000047740A9 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
WO2000047740A3 (en) Tnf-related proteins
WO2001085782A3 (en) Fusion receptor from TNF family
WO1998016551A3 (en) Variants of vascular endothelial cell growth factor having antagonistic properties
HK1062305A1 (en) Concatameric immunoadhesion
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
WO2003016522A3 (en) Methods and compounds for the targeting of protein to exosomes
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
NO965411L (en) N-terminally extended proteins expressed in yeast
WO1998031806A3 (en) Fc receptors and polypeptides
WO1999055868A3 (en) Fizz proteins
WO2005017149A8 (en) Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
WO2006001023A3 (en) Chimeric proteins and uses thereof
WO2001031014A3 (en) G protein-coupled receptors expressed in human brain
WO2004024750A3 (en) Cd44-binding ligands
WO2005035570A3 (en) Variants of cd40l protein
WO2003068802A3 (en) Materials and methods for preparing dimeric growth factors
AU6517400A (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
WO2000059942A3 (en) Human obesity protein binding protrein-2 homolog and uses thereof
ATE295890T1 (en) VECTOR FOR EXPRESSING N-TERMINALLY EXTENDED PROTEINS IN YEAST CELLS
EP1212340A4 (en) 29 human cancer associated proteins
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
AU6310100A (en) Single-chain polypeptides comprising troponin i n-terminal fragments and troponin
WO2003059281A3 (en) Novel variants of rankl protein
WO2001029224A3 (en) Granulocyte peptide homolog zgpa1
WO2003033665A3 (en) Secreted protein, ztnf9

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/19-19/19; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase